Search results for "benzimidazole"

showing 10 items of 161 documents

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

2010

SummaryThis trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. A total of 2,055 patients were randomised to 28–35 days treatment with oral dabigatran, 220 mg once-daily, starting with a half-dose 1–4 hours after surgery, or subcutaneous enoxaparin 40 mg once-daily, starting the evening before surgery. The primary efficacy outcome was a composite of total venous thromboembolism [VTE] (venographic or symptomatic) and death from all-causes. The main secondary composite outcome was major VTE (proximal deep-vein thrombosis or non-fatal pulmonary embol…

Malemedicine.medical_specialtymedicine.drug_classArthroplasty Replacement HipInjections SubcutaneousAdministration OralLow molecular weight heparinHemorrhage030226 pharmacology & pharmacyAntithrombinsDabigatranlaw.invention03 medical and health sciencesPostoperative Complicationsoral thromboprophylaxis dabigatran flebography0302 clinical medicineDouble-Blind MethodRandomized controlled triallawHumansMedicineEnoxaparinAgedVenous Thrombosisbusiness.industryAnticoagulantAnticoagulantsVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseSurvival AnalysisDabigatranSurgeryPulmonary embolismVenous thrombosisDirect thrombin inhibitorAnesthesiabeta-AlanineBenzimidazolesFemalebusinessEnoxaparin sodiummedicine.drugThrombosis and Haemostasis
researchProduct

Antihistaminic and anticholinergic activities of mequitazine in comparison with clemizole

1988

Abstract The antihistamine and anticholinergic properties of mequitazine have been investigated and compared with those of clemizole. Both mequitazine and clemizole antagonized the effect of histamine in guinea-pig ileum competitively, the pA2 values calculated by Schild plot were 9.95 ± 0.44 for mequitazine and 10.54 ± 0.44 for clemizole. Mequitazine at 10−7 M produced a parallel shift of the dose-response curve to acetylcholine in the rat duodenum, clemizole and the lower doses of mequitazine failed to modify the effect of acetylcholine. The potency of mequitazine and clemizole as H1-histamine blockers is similar, but only mequitazine at highest concentration used showed anticholinergic a…

medicine.medical_specialtyDuodenummedicine.drug_classmedicine.medical_treatmentGuinea PigsPharmaceutical ScienceIn Vitro TechniquesBiologyParasympatholyticchemistry.chemical_compoundPhenothiazinesInternal medicinemedicineAnticholinergicAnimalsPotencyMequitazinePharmacologyParasympatholyticsMuscle SmoothRats Inbred StrainsAcetylcholineRatsClemizoleSchild regressionEndocrinologychemistryHistamine H1 AntagonistsBenzimidazolesAntihistamineHistamineHistamineMuscle Contractionmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis

2018

Abstract: Chemotherapy is currently the only effective approach to treat all forms of leishmaniasis. However, its effectiveness is severely limited due to high toxicity, long treatment length, drug resistance, or inadequate mode of administration. As a consequence, there is a need to identify new molecular scaffolds and targets as potential therapeutics for the treatment of this disease. We report a small series of 1,2‐substituted‐1H‐benzo[d]imidazole derivatives (9ad) showing affinity in the submicromolar range (Ki = 0.150.69 μM) toward Leishmania mexicanaCPB2.8ΔCTE, one of the more promising targets for antileishmanial drug design. The compounds confirmed activity in vitro against intrace…

BenzimidazoleCell SurvivalIn silicoLeishmania mexicanaAntiprotozoal AgentsDrug Evaluation PreclinicalProtozoan ProteinsDrug resistanceCysteine Proteinase InhibitorsPharmacologyAntileishmanial agents Benzimidazole derivatives Docking studies In silico profiling Leishmania mexicanaCPB2.8 Biochemistry Molecular Medicine01 natural sciencesBiochemistryLeishmania mexicanaCell LineInhibitory Concentration 50chemistry.chemical_compoundCysteine ProteasesDrug DiscoverymedicineHumansAmastigoteLeishmaniasisBiologyEnzyme AssaysPharmacologyBinding Sitesbiology010405 organic chemistryChemistryPharmacology. TherapyOrganic ChemistryHydrogen BondingLeishmaniasisbiology.organism_classificationmedicine.diseaseLeishmaniaProtein Structure Tertiary0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryChemistryMolecular MedicineBenzimidazolesHuman medicineLeishmania infantumChemical biology and drug design
researchProduct

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

2019

Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition. We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD. Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD. The activity of compound MC1019 against the PLK1…

PBD Polo box domainMTD maximal tolerance doseCDC25 cell division cycle 25HIF-1α hypoxia-inducible factor 1 αMST microscale thermophoresisIC50 50% inhibition concentrationMFP M phase promoting factorPARP-1 poly(ADP-ribose) polymerase-10302 clinical medicineFOXO forkhead box ONec-1 necrostatin 1CDC2 cell division cycle protein 2 homologGeneral Pharmacology Toxicology and PharmaceuticsMitotic catastropheCDK cyclin-dependent kinase0303 health sciencesChemistryPolo-like kinaseMono-targeted therapyCell cycleBUBR1 budding uninhibited by benzimidazole-related 1Polo box domain030220 oncology & carcinogenesisPLK1 Polo-like kinaseNecroptosisSpindle damagePLK1IHC immunohistochemistryOriginal articleNecroptosisCell cyclePLK1APC/C anaphase-promoting complex/cyclosomePLK3ABC avidin-biotin complexPI propidium iodide03 medical and health sciencesFBS fetal bovine serumPDB Protein Data BankKd the dissociation constantKinase activity030304 developmental biologyAkt/PKB signaling pathwayCell growthlcsh:RM1-950LC3 light chain 3lcsh:Therapeutics. PharmacologyCancer researchDAPKs death-associated protein kinase3-MA 3-methyladenineDAPI 4′6-diamidino-2-phenylindoleSAC spindle assembly checkpointActa Pharmaceutica Sinica B
researchProduct

Pantoprazole: from drug metabolism to clinical relevance.

2008

Conditions requiring inhibition of acid secretion, such as gastro-oesophageal reflux disease (GORD), peptic ulcers, non-ulcer dyspepsia or the use of NSAIDs, are very common, and their prevalence is expecting to rise as they are seen predominantly amongst the elderly. Among the drugs available to inhibit acid secretion, proton pump inhibitors (PPI) have been shown to have the best efficacy-safety ratio and have been used widely.This paper was intended to provide an overall presentation of one of these PPIs, pantoprazole.This study was first intended to give an overview of pantoprazole, so a Medline search was conducted using pantoprazole as unique search term, without publication date restr…

medicine.medical_specialtyPeptic UlcerPepticRabeprazoleLansoprazoleToxicologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesEsomeprazoleInternal medicinemedicineHumansPantoprazoleOmeprazolePantoprazolePharmacologyClinical Trials as Topicbiologybusiness.industryProton Pump InhibitorsGeneral MedicineHelicobacter pyloribiology.organism_classificationAnti-Ulcer Agentsdigestive system diseasesTreatment OutcomeGastroesophageal RefluxbusinessDrug metabolismmedicine.drugExpert opinion on drug metabolismtoxicology
researchProduct

Effect of histamine and histamine analogues on human isolated myometrial strips.

1992

1. The effect of histamine and histamine H1- and H2-receptor agonists on isolated myometrium strips of premenopausal women has been examined. The effect of acetylcholine was also determined. 2. Histamine, 2-pyridylethylamine, 4-methylhistamine and acetylcholine, but not dimaprit, produced a concentration-related contractile response in human isolated myometrial strips. Histamine also produced a further contraction in human isolated myometrial strips precontracted with KCl (55 mM). 3. The contractile response to histamine was antagonized by the histamine H1-receptor antagonist, clemizole (0.1 microM) but was potentiated by the histamine H2-receptor antagonist, ranitidine (10 microM). Clemizo…

AdultAtropinemedicine.medical_specialtyPyridinesMuscle RelaxationHistamine H1 receptorRanitidineHistamine agonistPotassium ChlorideHistamine Agonistschemistry.chemical_compoundHistamine receptorUterine ContractionHistamine H2 receptorInternal medicinemedicineHumansPharmacologyDose-Response Relationship DrugMethylhistaminesMuscle SmoothMiddle AgedDimapritAcetylcholineClemizoleEndocrinologyMuscle relaxationchemistryMyometriumBenzimidazolesFemaleHistamineHistamineResearch ArticleBritish journal of pharmacology
researchProduct

The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.

2001

To determine the antihypertensive efficacy, effect duration and safety of the angiotensin II type 1 receptor blocker candesartan cilexetil and the angiotensin converting enzyme inhibitor enalapril once daily in patients with mild to moderate hypertension.A multicenter, randomised, double-blind parallel group study was performed in Finland, France, the Netherlands, Spain and Sweden. Three-hundred-and-ninety-five men and women in the age range 20-80 years with primary hypertension were randomised to an 8-week double-blind treatment period with either candesartan cilexetil 8-16 mg or enalapril 10-20 mg once daily, with forced dose titration after 4 weeks. Non-invasive ambulatory blood pressure…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureTime Factorsmedicine.medical_treatmentDiastoleTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood PressureAngiotensin Receptor AntagonistsDouble-Blind MethodEnalaprilHeart RateInternal medicineInternal MedicinemedicineHumansProdrugsEnalaprilAntihypertensive AgentsAgedAged 80 and overChemotherapybiologybusiness.industryBiphenyl CompoundsAngiotensin-converting enzymeGeneral MedicineMiddle AgedAngiotensin IICandesartanEndocrinologyTherapeutic EquivalencyACE inhibitorHypertensionbiology.proteinCardiologyBenzimidazolesFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugBlood pressure
researchProduct

Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant

1998

Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of palatable sweet solutions and to block the formation of conditioned place preferences; these effects are reversed by chronic treatment with tricyclic or atypical antidepressant drugs. The present study was designed to evaluate the antidepressant-like activity in this model of flibaserin (BIMT-17), a novel serotonergic agent with 5-HT1A receptor agonist and 5-HT2 receptor antagonist properties. Two experiments were conducted, using rats (experiment 1) and mice (experiment 2). In experiment 1, decreases in sucrose intake were seen in rats exposed to chronic mild stress, but the effect was unr…

MaleAgonistSucrosemedicine.medical_specialtyQuinpirolemedicine.drug_classMotor ActivityMiceSerotonin AgentsQuinpiroleDopamine receptor D3Dopamine receptor D2Internal medicineSalicylamidesmedicineAnimalsRats WistarPharmacologyRacloprideFluoxetinebusiness.industryBody WeightFeeding BehaviorConditioned place preferenceRatsEndocrinologyRacloprideAntidepressive Agents Second-GenerationConditioning OperantDopamine AntagonistsFlibanserinBenzimidazolesbusinessStress Psychologicalmedicine.drugEuropean Journal of Pharmacology
researchProduct

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

2019

Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P) in patients with chronic HCV genotype 1-6 infections and compensated liver disease, including patients with chronic kidney disease stages 4 or 5 (CKD 4/5). Methods: Data from 9 Phase II and III clinical trials, assessing the efficacy and safety of G/P treatment for 8-16 weeks, were included. The presence of cirrhosis was determined at screening using a liver …

CyclopropanesLiver CirrhosisMaleAminoisobutyric AcidsPyrrolidinesCirrhosisSustained Virologic Responseadverse eventHepacivirusmedicine.disease_causeGastroenterology0302 clinical medicine030212 general & internal medicinePathologie maladies infectieusesSulfonamidesmedicine.diagnostic_testLiver DiseasesPibrentasvirMicrobiologie et protistologie [entomologiephytoparasitolog.]Infectious DiseasesData Interpretation StatisticalLiver biopsyglecaprevir/pibrentasvirHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologycompensated cirrhosisMicrobiologie et protistologie [parasitologie hum. et anim.]Microbiology (medical)medicine.medical_specialtyGenotypeProlineLactams MacrocyclicHepatitis C virusAntiviral Agents03 medical and health sciencesLeucineQuinoxalinesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryGlecaprevirHepatitis C Chronicmedicine.diseaseBenzimidazolesMicrobiologie et protistologie [bacteriol.virolog.mycolog.]Transient elastographybusinesschronic kidney diseaseKidney diseaseClinical Infectious Diseases
researchProduct

Effect of carbendazim and physicochemical factors on the growth and ochratoxin A production of Aspergillus carbonarius isolated from grapes.

2007

Carbendazim is a systemic fungicide that is commonly used on several crops (tobacco, fruit, vegetables, cereals, etc.). This fungicide is used to control fungal infections in vineyards. It is indicated against Botrytis cinerea, Uncinula necator, Plasmopara viticola and other fungi and can be used either alone or coupled with other fungicides. However, there is a lack of in-depth studies to evaluate its effectiveness against growth of Aspergillus carbonarius isolated from grapes and OTA production. A medium based on red grape juice was used in this study. Preliminary studies were performed at 0.98 a(w) and 25 degrees C using carbendazim concentrations over a wide range (1-2000 ng/ml medium) …

Ochratoxin ATime FactorsMicrobiologyModels Biologicalchemistry.chemical_compoundBotanyVitisFood scienceMycotoxinOchratoxinBotrytis cinereaUncinula necatorAnalysis of VariancebiologyDose-Response Relationship DrugCarbendazimTemperaturefood and beveragesWaterGeneral Medicinebiology.organism_classificationOchratoxinsFungicides IndustrialFungicideKineticsAspergilluschemistryPlasmopara viticolaFood MicrobiologyBenzimidazolesCarbamatesFood ScienceInternational journal of food microbiology
researchProduct